ClinicalTrials.gg
RecruitingNCT06355791STABILITYUpdated Nov 5, 2026

Post-Market Clinical Study of Functional Motion Outcomes in Subjects Treated With the Minuteman Device

An interventional study of Minuteman G5 Device in Degenerative Conditions of the Lumbar Spine, Lumbar Spinal Stenosis and Spondylolisthesis, sponsored by Spinal Simplicity LLC. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Spinal Simplicity LLC · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.
Updated Nov 5, 2026Primary completion moved1 site addedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective, multi-center open-label single arm post-market study where the purpose is to evaluate the effectiveness and safety of the market approved Spinal Simplicity Minuteman G5 MIS Fusion Plate and bone graft material in patients with degenerative conditions of the lumbar spine resulting in chronic low back pain with lower extremity symptoms and concurrent neurogenic claudication. The indication for the device under study is degenerative conditions of the lumbar spine resulting in back pain with lower extremity symptoms and neurogenic claudication.

Read the detailed description

Up to 150 subjects will be enrolled and treated at up to 20 study sites. Qualified subjects will be enrolled and treated with the Minuteman G5 Device. Subjects will be seen at 1-, 3-, 6- and 12-months following study treatment.

Key outcome assessments will include gait and balance testing performed using BioMech Lab sensor technology to capture and deliver three-dimensional patient motion data to a mobile device that instantly analyzes, distills, and quantifies the information. Patient reported outcome measures will also be collected to evaluate pain, quality of life and satisfaction. During the primary assessment at 12-months post-treatment subject will be offered a computerized topography (CT) scan to evaluate spinal fusion.

After completion of the Month 12 visit all subjects will be asked to complete annual visits through 5 years, which include collection of PROMs, safety review, and can be completed in person or remote.

02

Conditions studied

  • Degenerative Conditions of the Lumbar Spine
  • Lumbar Spinal Stenosis
  • Spondylolisthesis
03

In context

Spinal Stenosis

458 studies on the registry are indexed under Spinal Stenosis; 105 are open to participants now.

This study's planned enrollment of 150 is above the median of 80 across 281 interventional studies indexed under Spinal Stenosis.

Browse Spinal Stenosis studies →

Lead sponsor

Spinal Simplicity LLC is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject must MEET ALL of the following inclusion criteria:

  1. Be a candidate for Spinal Simplicity Minuteman G5 Fusion Plate device per labeled indication
  2. Be willing and capable of giving written consent to participate in this clinical study based on voluntary agreement after a thorough explanation of the subject's participation has been provided
  3. Be willing and capable of subjective evaluation, read and understand written questionnaires, and read, understand the written
  4. Be 18 years of age or older at the time of enrollment
  5. Have been diagnosed with degenerative conditions of the lumbar spine resulting in chronic low back pain with lower extremity symptoms and concurrent neurogenic claudication
  6. Received at least 3 months of non-operative or conservative treatment without significant benefit in the opinion of the Investigator
  7. Be willing and able to comply with study-related requirements, procedures and visits
  8. Be on a stable pain medication regimen, as determined by the Investigator, for at least 30 days prior to enrolling in this study.
  9. Must disclose any unresolved major issues of secondary gain (e.g., social, financial, legal), as determined by the Investigator. Including being involved in an injury claim under current litigation or has a pending or approved worker's compensation claim. Subjects will not be excluded due to secondary gain, but it should be disclosed at Enrollment.

Exclusion criteria

Exclusion Criteria

A subject must NOT MEET ANY of the following exclusion criteria:

  1. Had previous spinal surgery at the level of intervention (e.g. lumbar fusion, discectomy, Laminectomy) MILD procedure is not considered an exclusion.
  2. Patient physically unable to perform the Gait and/or Balance tests.
  3. Current systemic infection or local infection increasing the risk of surgery
  4. History of medications decreasing bone quality or soft tissue healing in the opinion of the Investigator
  5. Grade II-V spondylolisthesis
  6. Significant scoliosis with Cobb angle >10 degrees
  7. Unremitting back pain in a spinal flexion position
  8. Active systemic disease that may affect the welfare of the subject in the opinion of the Investigator
  9. Be concurrently participating in another clinical drug and/or device study that may alter or confound the results of the assessment ( device, investigational drug, new indication for a device or drug, or additional testing beyond standard of care procedures) as determined by the investigator.
  10. Vertebral osteoporosis or history of vertebral fracture
  11. Be pregnant/ lactating or plan to become pregnant from study enrollment through 3 months post-operatively. (determined by urine testing unless female subject is surgical sterile or ). If female, sexually active and childbearing age, subject must be willing to use a reliable form of through the 3-month visit.
  12. Malformation or dysplasia of spinous process
  13. Severe osteoporosis with T score \<-2.5 SD
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Other
    Surgical Group

    patient treated with Minuteman G5 interspinous fusion device 510k cleared for degenerative conditions of the lumbar spine

    Device: Minuteman G5 Device

Interventions

  • DeviceMinuteman G5 Device

    The Minuteman G5 MIS Fusion Plate consists of spinous process plates and surgical instruments. Implants are made of Titanium alloy

06

What researchers measure

Primary outcomes

  1. Pain (Overall, Back and Leg) using NRS/numeric rating scale

    Overall pain, as well as back pain when standing/walking and leg pain when standing will be assessed using a numeric rating scale (NRS). The NRS is a pain screening tool, commonly used to assess pain severity at that moment in time using a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable.

    Time frame: Baseline and 1-, 3-, 6- and 12-months post implantation; annually out to five years.

  2. Oswestry Disability Index (ODI)

    ODI is a self-reported questionnaire widely used to track changes in a patient's condition over time and evaluate the effectiveness of treatments for low back pain. The ODI consists of 10 sections, each addressing a specific aspect of daily functioning. A higher score indicates greater disability. The final score/index ranges from 0-100 scale. A score of 0-20 reflects minimal disability, 21-40 moderate disability, 41-60 severe disability, 61-80 crippled, and 81-100 bed-bound.

    Time frame: Baseline and 1-, 3-, 6- and 12-months post implantation; annually out to five years.

  3. PROMIS 29 2.0

    PROMIS-29 c2.0 is a set of standardized questions that measures 29 items across 7 domains of physical and mental health. PROMIS-29 profile assesses pain intensity using a single 0-10 numeric rating scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable. And seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) using four items per domain. Each domain is scored on T-Score Scale ranging between 22.9- 81.6 with a mean of 50 and a standard deviation of 10.

    Time frame: Baseline and 1-, 3-, 6- and 12-months post implantation; annually out to five years.

  4. Assessment of Motion using BioMech Lab testing equipment

    A Primary Objective of this study is to collect real-world functional outcomes assessment of motion following treatment with the market-released Spinal Simplicity Minuteman G5 Device using BioMech Lab equipment to record gait and balance. The BioMech Lab motion analytics system will assess gait and balance via sensors placed before physical testing.

    Time frame: Baseline and 1-, 3- and 12-months post implantation.

  5. Zurich Classification Questionnaire (ZCQ)

    The ZCQ Symptom Severity, Physical Function and Subject Satisfaction allows subjects to rate their symptoms, function or satisfaction on a scale based on their experience over the past week. Symptom Severity domain evaluates the intensity of symptoms such as pain and numbness. It comprises seven items, each rated on a scale from 1 to 5. Overall symptom score ranges from 7-49; with higher scores indicating more severe symptoms. Physical Function domain assesses the impact of symptoms on daily activities. It includes five items, scored on a 1 to 4 scale. Overall symptom score ranges from 5-20; where higher scores denote greater functional impairment. Subject Satisfaction domain measures patient satisfaction with treatment outcomes. It consists of six items, each rated from 1 to 4, with higher scores reflecting greater dissatisfaction. Overall Satisfaction ranges from 6-24: where higher scores denote greater dissatisfaction.

    Time frame: Baseline and 1-, 3- 6- and 12-months post implantation; annually out to five years.

Secondary outcomes

  1. Spinal Fusion Assessment based on review of Lumbar Computerized Tomography (CT) Scan

    The secondary objective is to assess spinal fusion at 12 months post-operative using a Fusion Assessment Scale provided by Spinal Simplicity based on review of Lumbar CT Scan.

    Time frame: Collected at 12 months post implantation.

07

Study locations

6 of 7 sites recruiting
  • Vista Clinical Research
    Newnan, Georgia 30265, United States
    Recruiting
    • Debra Helton · Contact
    • Sandeep Vaid, MD · Principal investigator
  • Comprehensive Pain & Spine Specialists
    Indianapolis, Indiana 46250, United States
    Recruiting
    • Esther Owusu · Contact
    • Andrew Trobridge, MD · Principal investigator
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
    Not yet recruiting
    • Manuel Clark · Contact
    • Usman Latif, MD, MBA · Principal investigator
    • Dawood Sayed, MD · Sub investigator
  • Paradigm Health System
    Slidell, Louisiana 70458, United States
    Recruiting
  • Nura Precision Pain Management
    Edina, Minnesota 55435, United States
    Recruiting
    • Ken Farmer · Contact
    • R. Scott Stayner, MD · Principal investigator
  • Pacific Sports & Spine
    Eugene, Oregon 97404, United States
    Recruiting
    • Katie Fabian · Contact
    • Gregory Moore, MD · Principal investigator
  • Spine & Nerve Center of the Virginias
    Charleston, West Virginia 25301, United States
    Recruiting
    • Amy Young, RN-RC · Contact
    • Timothy Deer, MD · Principal investigator
    • Christopher Kim, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Patients will be deidentified with unique study ID. Any study will be anonymized.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2027, 43 months after the start.

Of 123 interventional studies with no phase under Spinal Stenosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 50. This study's planned 43 months is above that.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2027, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2024
First posted
Apr 9, 2024
StartActual
May 29, 2024
Primary completionEst.
Dec 2027was Dec 2026
CompletionEst.
Dec 2030
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Paradigm Health System · Slidell, United States
Nov 5, 2026
Primary completion
Dec 2026→Dec 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    1 site added
    Show site
    • Paradigm Health System · Slidell, United States
    Primary completion Dec 2026→Dec 2027
    + 2 other changes: verification date and documents

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06355791
Lead sponsor
Spinal Simplicity LLC
Responsible party
Sponsor
First posted
Apr 9, 2024
Start date
May 29, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 5, 2026

Study contacts

Echo Cundiff
Contact
ecundiff@spinalsimplicity.com
913-451-4414
Adam Rogers
Contact
arogers@spinalsimplicity.com
913-451-4414
Tom Hedman, PhD
study chair · Spinal Simplicity

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion